TrialTherapeutics and clinical risk management2025

Adverse Event Management in Patients with Platinum-Resistant Ovarian Cancer Treated with Niraparib and Anlotinib: Updates from the Phase II, Multi-Center ANNIE Study.

Ting Deng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.